Skip to main content

Table 1 Demographic and HIV-related parameters

From: Acceptance and tolerability of an adjuvanted nH1N1 vaccine in HIV-infected patients in the Cologne-Bonn cohort

Tolerability Study Group HIV infected patients vaccinated against pandemic influenza in the two centres who returned their patient's diary
Acceptance Study Group HIV infected patients, eligible for active immunization, who visited the Cologne outpatient clinic in the predefined time period
SD Standard deviation
ART Antiretroviral therapy
  Tolerability Study Group Acceptance Study Group
N (total) 475 538
Male:Female 387:88 447:91
Mean age, years (SD) 45 ( ± 9) 45 ( ± 9)
Caucasian, N (%) 404 (85%) 453 (84%)
Mean absolute CD4-cells/ μl (SD) 498 ( ± 194) 483 ( ± 177)
HIV-RNA < 50 copies/ ml, N (%) 336 (77%) 393 (73%)
ART treatment, N (%) 412 (87%) 462 (86%)